IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 369 filers reported holding IONIS PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 1.27 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $8,542,864 | +66.8% | 179,246 | +51.7% | 0.00% | +100.0% |
| Q1 2024 | $5,121,022 | -34.3% | 118,132 | -23.4% | 0.00% | -50.0% |
| Q4 2023 | $7,799,156 | -32.2% | 154,164 | -39.2% | 0.00% | -50.0% |
| Q3 2023 | $11,498,352 | +158.7% | 253,491 | +134.0% | 0.00% | +300.0% |
| Q2 2023 | $4,444,534 | +19.7% | 108,324 | +4.3% | 0.00% | -50.0% |
| Q1 2023 | $3,713,422 | +756.4% | 103,901 | +805.1% | 0.00% | – |
| Q4 2022 | $433,599 | -52.5% | 11,480 | -44.4% | 0.00% | – |
| Q3 2022 | $913,000 | -72.9% | 20,629 | -77.3% | 0.00% | -100.0% |
| Q2 2022 | $3,364,000 | -12.9% | 90,889 | -12.9% | 0.00% | 0.0% |
| Q1 2022 | $3,862,000 | -20.2% | 104,291 | -34.4% | 0.00% | -50.0% |
| Q4 2021 | $4,837,000 | +10.6% | 158,950 | +21.9% | 0.00% | +100.0% |
| Q3 2021 | $4,373,000 | -4.7% | 130,376 | +13.3% | 0.00% | -50.0% |
| Q2 2021 | $4,591,000 | -17.2% | 115,117 | -6.6% | 0.00% | -33.3% |
| Q1 2021 | $5,543,000 | -44.1% | 123,263 | -29.7% | 0.00% | -25.0% |
| Q4 2020 | $9,914,000 | +32.9% | 175,342 | +11.5% | 0.00% | 0.0% |
| Q3 2020 | $7,460,000 | -8.0% | 157,216 | +14.3% | 0.00% | -20.0% |
| Q2 2020 | $8,108,000 | +122.8% | 137,526 | +78.7% | 0.01% | +66.7% |
| Q1 2020 | $3,639,000 | +39.8% | 76,976 | +78.6% | 0.00% | -25.0% |
| Q4 2019 | $2,603,000 | +1056.9% | 43,093 | +1049.1% | 0.00% | – |
| Q3 2019 | $225,000 | -65.0% | 3,750 | -62.5% | 0.00% | -100.0% |
| Q2 2019 | $643,000 | -12.8% | 10,007 | +10.2% | 0.00% | 0.0% |
| Q1 2019 | $737,000 | -62.0% | 9,082 | -74.7% | 0.00% | -75.0% |
| Q4 2018 | $1,942,000 | -20.0% | 35,928 | -23.6% | 0.00% | -20.0% |
| Q3 2018 | $2,426,000 | +187.4% | 47,026 | +145.7% | 0.01% | +150.0% |
| Q1 2018 | $844,000 | -19.5% | 19,143 | -8.2% | 0.00% | -50.0% |
| Q4 2017 | $1,049,000 | +323.0% | 20,854 | +325.6% | 0.00% | +300.0% |
| Q3 2017 | $248,000 | +9.3% | 4,900 | +9.7% | 0.00% | 0.0% |
| Q2 2017 | $227,000 | -74.8% | 4,465 | -80.1% | 0.00% | -75.0% |
| Q1 2017 | $901,000 | -49.6% | 22,405 | -40.0% | 0.00% | -50.0% |
| Q4 2016 | $1,787,000 | +103.5% | 37,366 | +56.0% | 0.01% | +100.0% |
| Q3 2016 | $878,000 | -82.2% | 23,950 | -88.7% | 0.00% | -84.0% |
| Q2 2016 | $4,919,000 | +206.1% | 211,203 | +432.1% | 0.02% | +177.8% |
| Q1 2016 | $1,607,000 | -55.7% | 39,690 | -32.3% | 0.01% | -59.1% |
| Q4 2015 | $3,628,000 | – | 58,588 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sicart Associates LLC | 367,360 | $14,768,000 | 10.67% |
| BB BIOTECH AG | 7,461,295 | $299,944,000 | 9.81% |
| TANAKA CAPITAL MANAGEMENT INC | 83,399 | $3,353,000 | 7.39% |
| DOWLING & YAHNKE LLC | 675,843 | $27,169,000 | 2.89% |
| Opus Point Partners Management, LLC | 78,900 | $3,172,000 | 2.35% |
| Motley Fool Asset Management LLC | 259,000 | $10,412,000 | 2.25% |
| ARK Investment Management | 127,563 | $5,128,000 | 1.48% |
| Motley Fool Wealth Management, LLC | 325,965 | $13,104,000 | 1.26% |
| PINNACLE ASSOCIATES LTD | 1,514,710 | $60,891,000 | 1.16% |
| Bellevue Group AG | 205,253 | $8,251,000 | 1.10% |